Vaccine · 2026
Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: A retrospective cohort study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kitano Taito, Hashimoto Eriko, Sado Toshiyuki, Yoshida Sayaka
Аннотация
BACKGROUND: This study assessed effectiveness of respiratory syncytial virus (RSV) vaccination in mothers.
METHODS: This retrospective cohort study used TriNetX, a database of multicenter health records with the US as the major contributor. Eligible participants were pregnant women with a medical encounter at 28 weeks of gestation or later and who underwent RSV testing between September 2023 and February 2026. After propensity score matching, the effectiveness of the vaccine against maternal RSV infection was estimated based on risk ratio between the vaccinated and unvaccinated groups.
RESULTS: Of 2440 and 17,537 vaccinated and unvaccinated patients in the US, 2434 patients from each group were matched. The vaccine effectiveness against RSV infection in vaccinated mothers for 12 months after maternal RSV vaccination was estimated to be 82.1% (95% confidence interval 67.0%-90.3%).
CONCLUSIONS: The maternal RSV vaccination was effective against RSV infection in mothers, indicating an additional benefit of maternal RSV vaccination.
METHODS: This retrospective cohort study used TriNetX, a database of multicenter health records with the US as the major contributor. Eligible participants were pregnant women with a medical encounter at 28 weeks of gestation or later and who underwent RSV testing between September 2023 and February 2026. After propensity score matching, the effectiveness of the vaccine against maternal RSV infection was estimated based on risk ratio between the vaccinated and unvaccinated groups.
RESULTS: Of 2440 and 17,537 vaccinated and unvaccinated patients in the US, 2434 patients from each group were matched. The vaccine effectiveness against RSV infection in vaccinated mothers for 12 months after maternal RSV vaccination was estimated to be 82.1% (95% confidence interval 67.0%-90.3%).
CONCLUSIONS: The maternal RSV vaccination was effective against RSV infection in mothers, indicating an additional benefit of maternal RSV vaccination.